Literature DB >> 11193173

Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein.

P J Kahle1, M Neumann, L Ozmen, C Haass.   

Abstract

The 15-20 kDa synuclein (SYN) phosphoproteins are abundantly expressed in nervous tissue. Members of the family include alpha- and beta-SYN, and the more distantly related gamma-SYN and synoretin. SYN genes have been identified in Torpedo, canary, and several mammalian species, indicating an evolutionary conserved role. Expression of alpha-SYN was found to be modulated in situations of neuronal remodeling, namely, songbird learning and after target ablation of dopaminergic striatonigral neurons in the rat. The presynaptic localization of alpha-SYN is further supportive of a direct physiological role in neuronal plasticity. The extensive synaptic co-localization of alpha- and beta-SYN might indicate functional redundancy of these highly homologous synucleins. However, alpha-SYN was the only family member identified in Lewy bodies and cytoplasmic inclusions characteristic for multiple system atrophy. Moreover, alpha-SYN was genetically linked to familial Parkinson's disease. The two Parkinson's disease-associated mutations accelerated the intrinsic aggregation property of alpha-SYN in vitro. Post-translational modifications, such as phosphorylation and proteolysis, and/or interaction with other proteins, might regulate alpha-SYN fibril formation in vivo. Cytoskeletal elements and signal transduction intermediates have been recently identified as binding partners for alpha-SYN. Preliminary data available from transgenic mice suggest that (over)expressed human alpha-SYN proteins are less efficiently cleared from the neuronal cytosol. Thus, Parkinson's disease-associated mutations might perturb axonal transport, leading to somal accumulation of alpha-SYN and eventually Lewy body formation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11193173     DOI: 10.1111/j.1749-6632.2000.tb06902.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  39 in total

1.  Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization.

Authors:  Judith Eschbach; Björn von Einem; Kathrin Müller; Hanna Bayer; Annika Scheffold; Bradley E Morrison; K Lenhard Rudolph; Dietmar R Thal; Anke Witting; Patrick Weydt; Markus Otto; Michael Fauler; Birgit Liss; Pamela J McLean; Albert R La Spada; Albert C Ludolph; Jochen H Weishaupt; Karin M Danzer
Journal:  Ann Neurol       Date:  2014-12-19       Impact factor: 10.422

2.  Biochemical and morphological consequences of human α-synuclein expression in a mouse α-synuclein null background.

Authors:  Kavita Prasad; Elizabeth Tarasewicz; Pamela A Ohman Strickland; Michael O'Neill; Stephen N Mitchell; Kalpana Merchant; Samnang Tep; Kathryn Hilton; Akash Datwani; Manuel Buttini; Sarah Mueller-Steiner; Eric K Richfield
Journal:  Eur J Neurosci       Date:  2011-01-28       Impact factor: 3.386

3.  Aggregate clearance of α-synuclein in Saccharomyces cerevisiae depends more on autophagosome and vacuole function than on the proteasome.

Authors:  Doris Petroi; Blagovesta Popova; Naimeh Taheri-Talesh; Stefan Irniger; Hedieh Shahpasandzadeh; Markus Zweckstetter; Tiago F Outeiro; Gerhard H Braus
Journal:  J Biol Chem       Date:  2012-06-21       Impact factor: 5.157

4.  Allostery in a disordered protein: oxidative modifications to α-synuclein act distally to regulate membrane binding.

Authors:  Eva Sevcsik; Adam J Trexler; Joanna M Dunn; Elizabeth Rhoades
Journal:  J Am Chem Soc       Date:  2011-04-14       Impact factor: 15.419

Review 5.  Targeting the chameleon: a focused look at α-synuclein and its roles in neurodegeneration.

Authors:  Blanca A Silva; Leonid Breydo; Vladimir N Uversky
Journal:  Mol Neurobiol       Date:  2012-09-01       Impact factor: 5.590

6.  α-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy.

Authors:  Benjamin Ettle; Bilal E Kerman; Elvira Valera; Clarissa Gillmann; Johannes C M Schlachetzki; Simone Reiprich; Christian Büttner; Arif B Ekici; André Reis; Michael Wegner; Tobias Bäuerle; Markus J Riemenschneider; Eliezer Masliah; Fred H Gage; Jürgen Winkler
Journal:  Acta Neuropathol       Date:  2016-04-08       Impact factor: 17.088

7.  Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein.

Authors:  Katerina E Paleologou; Adrian W Schmid; Carla C Rospigliosi; Hai-Young Kim; Gonzalo R Lamberto; Ross A Fredenburg; Peter T Lansbury; Claudio O Fernandez; David Eliezer; Markus Zweckstetter; Hilal A Lashuel
Journal:  J Biol Chem       Date:  2008-03-14       Impact factor: 5.157

8.  Phosphorylation of synucleins by members of the Polo-like kinase family.

Authors:  Martial K Mbefo; Katerina E Paleologou; Ahmed Boucharaba; Abid Oueslati; Heinrich Schell; Margot Fournier; Diana Olschewski; Guowei Yin; Markus Zweckstetter; Eliezer Masliah; Philipp J Kahle; Harald Hirling; Hilal A Lashuel
Journal:  J Biol Chem       Date:  2009-11-04       Impact factor: 5.157

9.  The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.

Authors:  Saurabh Sen; Andrew B West
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

10.  Drug Targeting of alpha-Synuclein Oligomerization in Synucleinopathies.

Authors:  Tiago Fleming Outeiro; Aleksey Kazantsev
Journal:  Perspect Medicin Chem       Date:  2008-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.